Category: Bioscience

For the past 20 years, Dr. Charlie Wilson has been a faculty member at Delaware State as part of a career that has also included stops at the University of Delaware (1988–94) and AstraZeneca (’94–97). A former wrestler and track athlete for the Hornets, Wilson holds a Ph.D. in Molecular Biology from UD. At Delaware…

For the past 22 years, John Koh has been a professor of Chemistry and Biochemistry at the University of Delaware. Since January 2017, he has been the interim director of UD’s Delaware Biotechnology Institute — after six years as associate director under Kelvin Lee. The Institute is responsible for helping a variety of constituencies obtain…

Things have been moving quickly at ACROBiosystems. But while it’s often said that speed comes at the expense of quality, the work being done by the company is decidedly first-rate and ahead of that done by competitors. “In just a short amount of time, we have gone from a startup to being one of the…

Trevor Brown has no grandiose dreams of solving the nation’s opioid epidemic single-handedly with his company’s drug disposal pouches. Instead, the CEO of DEact Medical Solutions is interested in being part of a broad-based approach to ending the deaths and addiction. As his company moves into its second year of existence, that vision is getting…

The biosciences climate in Delaware is robust and making a significant difference in finding cures for the most aggressive diseases and conditions. Eighty percent of the U.S. pharmaceuticals industry is headquartered in the First State and the surrounding states of Pennsylvania and New Jersey, according to Delaware Prosperity Partnership. Global bioscience giants with significant operations…

In the fast-moving world of biopharmaceuticals, the University of Delaware is preparing to demonstrate the importance of being NIIMBL. Launched at UD’s Delaware Biotechnology Institute last year, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is moving from its startup and organizational phase into working on developing new technology, says Kelvin Lee, the institute’s…

Reid Huber, executive vice president and chief scientific officer at Incyte, has a simple formula for how the company can keep ahead in a drug therapy environment that is moving more rapidly every year. “Speed, creativity and thinking 12 steps ahead is where the action is,” he says. That mantra is helping to fuel Incyte’s…

When some people think about LiteCure, they focus on the Newark-based company’s affiliations with professional and college teams across the country. Its laser wand is capable of relieving pain, stimulating healing and helping athletes get back to competition more quickly than other therapies. But LiteCure CEO Brian Pryor is much more interested in describing the…

Delaware BioScience Association last week announced plans to move out of the STAR Campus in Newark and into the former AstraZeneca North Campus on Concord Pike. The life sciences industry group will occupy a 3,500 square-foot facility facing Concord Pike near the entrance of the campus. “As a connector organization, collaboration is critical to our…

A breakthrough in gene editing and the announcement of a scholarship fund were just some of the highlights of the 2018 Delaware Bio Gala on Thursday, which also featured a “fireside chat” with the leaders of Incyte and Newark-based National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). More than 300 executives, researchers and scientists from the state’s…